Skip to main content
Steven Quay, MD, Pathology, Seattle, WA

Steven Carl Quay MD PhD

Cytopathology, Anatomic Pathology, Clinical Pathology


CEO and President, Atossa Therapeutics, Inc. (NASDAQ: ATOS)

Join to View Full Profile
  • 107 Spring StreetSuite 510Seattle, WA 98104

Dr. Quay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Massachusetts General Hospital
    Mass General Brigham/Massachusetts General HospitalResidency, Pathology-Anatomic and Clinical, 1978 - 1980
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 1977

Certifications & Licensure

  • DC State Medical License
    DC State Medical License Current
  • DE State Medical License
    DE State Medical License Current
  • VT State Medical License
    VT State Medical License Current
  • NH State Medical License
    NH State Medical License 2012 - Present
  • WA State Medical License
    WA State Medical License 1995 - 2026
  • CA State Medical License
    CA State Medical License 1980 - 2025
  • MA State Medical License
    MA State Medical License 1979 - 2025
  • Anatomic Pathology
    American Board of Pathology Anatomic Pathology
  • Join now to see all

Publications & Presentations

PubMed

Press Mentions

  • Happy Hour Continues: Alcohol and Breast Cancer Advisory
    Happy Hour Continues: Alcohol and Breast Cancer AdvisoryJanuary 9th, 2025
  • Happy Hour Is on the Rocks: Alcohol and Breast Cancer Advisory
    Happy Hour Is on the Rocks: Alcohol and Breast Cancer AdvisoryJanuary 8th, 2025
  • Atossa to Present a Trial in Progress Poster on Its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
    Atossa to Present a Trial in Progress Poster on Its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 9th, 2023
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: